A General Framework for Inhibitor Resistance in Protein Kinases
- 25 August 2011
- journal article
- research article
- Published by Elsevier BV in Cell Chemical Biology
- Vol. 18 (8), 966-975
- https://doi.org/10.1016/j.chembiol.2011.04.013
Abstract
No abstract availableThis publication has 44 references indexed in Scilit:
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK InhibitorsNew England Journal of Medicine, 2010
- Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design StrategiesJournal of Medicinal Chemistry, 2009
- Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinasesProceedings of the National Academy of Sciences of the United States of America, 2005
- The kinase haspin is required for mitotic histone H3 Thr 3 phosphorylation and normal metaphase chromosome alignmentGenes & Development, 2005
- Characterization of a Conserved Structural Determinant Controlling Protein Kinase Sensitivity to Selective InhibitorsCell Chemical Biology, 2004
- Glivec (STI571, imatinib), a rationally developed, targeted anticancer drugNature Reviews Drug Discovery, 2002
- High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistanceBlood, 2002
- Protein kinases — the major drug targets of the twenty-first century?Nature Reviews Drug Discovery, 2002
- Magic bullets for protein kinasesTrends in Cell Biology, 2001
- Potential positive and negative autoregulation of p60c-src by intermolecular autophosphorylation.Proceedings of the National Academy of Sciences of the United States of America, 1988